We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+7.64%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$6.56B
AUM Growth
+$19.4M
Cap. Flow
-$249M
Cap. Flow %
-3.79%
Top 10 Hldgs %
37.22%
Holding
183
New
22
Increased
65
Reduced
79
Closed
14

Top Buys

Rank Stock Value
1
DXCM icon
DexCom
DXCM
+$38.5M
2
SAGE
Sage Therapeutics
SAGE
+$22M
3
SIBN icon
SI-BONE Inc
SIBN
+$19.1M
4
STE icon
Steris
STE
+$16.6M
5
CLDX icon
Celldex Therapeutics
CLDX
+$15.6M

Top Sells

Rank Stock Value
1
AXNX
Axonics, Inc. Common Stock
AXNX
+$114M
2
ISRG icon
Intuitive Surgical
ISRG
+$56.6M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$51.2M
4
VRTX icon
Vertex Pharmaceuticals
VRTX
+$28.6M
5
EVH icon
Evolent Health
EVH
+$28.5M

Sector Composition

Rank Sector Weight
1 Healthcare 99.12%
2 Industrials 0.77%
3 Technology 0.02%
4 Communication Services 0.02%
5 Consumer Staples 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MOH icon
51
Molina Healthcare
MOH
$11.7B
$41M 0.63%
99,883
+8,407
+9% +$3.26M
MRK icon
52
Merck
MRK
$315B
$41M 0.63%
310,851
+20,645
+7% +$2.54M
PEN icon
53
Penumbra
PEN
$12.5B
$40.4M 0.62%
181,158
-21,888
-11% -$5.41M
COO icon
54
Cooper Companies
COO
$14B
$40.3M 0.61%
397,373
+53,225
+15% +$5.15M
BEAM icon
55
Beam Therapeutics
BEAM
$2.83B
$39.4M 0.6%
1,193,121
+498,300
+72% +$15.5M
VEEV icon
56
Veeva Systems
VEEV
$31.7B
$39M 0.59%
168,247
-26,766
-14% -$5.78M
SRRK icon
57
Scholar Rock
SRRK
$6.33B
$38.5M 0.59%
2,165,203
-3,722
-0.2% -$58.6K
ZBH icon
58
Zimmer Biomet
ZBH
$17.6B
$37.2M 0.57%
282,217
+1,129
+0.4% +$141K
FATE icon
59
Fate Therapeutics
FATE
$324M
$35.5M 0.54%
4,839,779
-11,800
-0.2% -$73K
SWAV
60
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
$34.4M 0.53%
105,786
-19,024
-15% -$4.67M
SRPT icon
61
Sarepta Therapeutics
SRPT
$1.82B
$32.6M 0.5%
251,521
+14,235
+6% +$1.74M
COR icon
62
Cencora
COR
$59.9B
$32M 0.49%
131,504
+5,378
+4% +$1.24M
GMED icon
63
Globus Medical
GMED
$10.5B
$31.1M 0.47%
579,898
-27,874
-5% -$1.5M
CI icon
64
Cigna
CI
$74.5B
$28.9M 0.44%
79,645
-8,825
-10% -$2.91M
CNC icon
65
Centene
CNC
$32.8B
$28.5M 0.43%
363,100
-78,753
-18% -$6.08M
BMRN icon
66
BioMarin Pharmaceuticals
BMRN
$11.5B
$28.1M 0.43%
321,787
-3,989
-1% -$357K
APLS
67
DELISTED
Apellis Pharmaceuticals
APLS
$27.9M 0.42%
473,915
-347,885
-42% -$22.2M
SILK
68
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
$27.8M 0.42%
1,518,230
+82,548
+6% +$1.31M
CSTL icon
69
Castle Biosciences
CSTL
$733M
$27M 0.41%
1,220,085
-12,293
-1% -$267K
TMDX icon
70
Transmedics
TMDX
$2.56B
$26.9M 0.41%
364,064
-154,826
-30% -$12.8M
ESPR
71
DELISTED
Esperion Therapeutics
ESPR
$26.7M 0.41%
9,944,064
+5,739,800
+137% +$13.9M
WVE icon
72
Wave Life Sciences
WVE
$1.12B
$25.3M 0.39%
4,094,458
-400,000
-9% -$2M
NTRA icon
73
Natera
NTRA
$38.9B
$24.7M 0.38%
269,832
+13,248
+5% +$996K
TMO icon
74
Thermo Fisher Scientific
TMO
$198B
$23.2M 0.35%
39,956
+4,614
+13% +$2.59M
HOLX
75
DELISTED
Hologic
HOLX
$22.6M 0.34%
289,969
+105
+0% +$7.81K
1 2
3
4 5

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q1 2024 Portfolio in Review

As of Q1 2024, Bellevue Group held 183 positions worth $6.56B, up 0.3% from $6.54B the previous quarter. Its ten largest holdings account for 37% of the portfolio.

Bellevue Group withdrew a net $249M in Q1 2024, closing 14 positions and reducing 79 holdings. Its most notable exit was Axonics, Inc. Common Stock, an estimated $114M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Industrials and Technology.

Against the trend, Bellevue Group opened a new position in Steris worth $16.5M.

  • Bellevue Group's largest Q1 2024 buy was Steris: 73,434 shares worth $16.5M.
  • Bellevue Group added most to DexCom in Q1 2024, an estimated $38.5M increase.
  • Bellevue Group's biggest Q1 2024 reduction was Intuitive Surgical, cutting an estimated $56.6M.
  • Bellevue Group fully exited Axonics, Inc. Common Stock in Q1 2024, selling an estimated $114M.
  • Bellevue Group's ten largest holdings make up 37% of its $6.56B portfolio in Q1 2024.
  • Bellevue Group opened 22 new positions and closed 14 in Q1 2024.
  • Bellevue Group's portfolio value rose 0.3% quarter-over-quarter to $6.56B.

Based on Bellevue Group's 13F filing for Q1 2024, filed 15 May 2024.